ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
OBI Pharma Granted Orphan Drug Designation for ADC Targeted Cancer Therapy
January 06, 2020OBI Pharma announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Pancreatic Cancer. OBI-999 is a first-in-class antibody drug conjugate targeting Globo H, a glycolipid antigen. -
US FDA grants ODD for OBI Pharma’s OBI-888 to treat pancreatic cancer
November 29, 2018Taiwan, Chinaese biopharma company OBI Pharma has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for OBI-888 to treat pancreatic cancer patients...... -
OBI Pharma receives FDA ODD for OBI-3424
September 29, 2018OBI-3424 is a first in class DNA alkylating cancer therapeutic agent targeting aldo-keto reductase 1C3 (AKR1C3) overexpressing cancers.
Pharma Sources Insight January 2025
